Cover Image

Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions: short report

We investigated the impact of disease-modifying therapies (DMTs) on the evolving tissue damage in iron rim multiple sclerosis lesions using a novel post-processing magnetic resonance imaging (MRI) approach, the T1/T2 ratio. In this study, on baseline and 1-year follow-up, T1/T2 ratios of iron rim le...

Full description

Saved in:
Bibliographic Details
Main Authors: Eisele, Philipp (Author) , Wittayer, Matthias Sebastian (Author) , Weber, Claudia Ellen (Author) , Platten, Michael (Author) , Schirmer, Lucas (Author) , Gass, Achim (Author)
Format: Article (Journal)
Language:English
Published: December 2022
In: Multiple sclerosis journal
Year: 2022, Volume: 28, Issue: 14, Pages: 2294-2298
ISSN:1477-0970
DOI:10.1177/13524585221106338
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/13524585221106338
Get full text
Author Notes:Philipp Eisele, Matthias Wittayer, Claudia E Weber, Michael Platten, Lucas Schirmer and Achim Gass
Description
Summary:We investigated the impact of disease-modifying therapies (DMTs) on the evolving tissue damage in iron rim multiple sclerosis lesions using a novel post-processing magnetic resonance imaging (MRI) approach, the T1/T2 ratio. In this study, on baseline and 1-year follow-up, T1/T2 ratios of iron rim lesions (IRLs) in patients starting DMT (dimethyl fumarate, fingolimod, ocrelizumab) did not statistically differ compared to patients without DMT. At the second follow-up, T1/T2 ratios were significantly lower in IRLs in patients without DMT (p = 0.002), suggesting that DMTs have a beneficial delayed effect on lesion evolution and tissue matrix damage in IRLs.
Item Description:Online veröffentlicht: 1. Juli 2022
Gesehen am 30.05.2023
Physical Description:Online Resource
ISSN:1477-0970
DOI:10.1177/13524585221106338

Similar Items